Clevexel Pharma invests in the development of new molecules between proof-of-concept in animals and proof-of-concept in humans.

In November 2013 Clevexel entered into a partnering agreement with Dynamix Pharmaceuticals, an Israeli biopharmaceutical company, to develop novel oral treatment for rheumatoid arthritis. Under the agreement, Clevexel and Dynamix will jointly cover the development of a dual mechanism SYK/JAK molecule in rheumatoid arthritis (RA). The collaboration aims to bring the rheumatoid arthritis project to a clinical proof of concept stage. Preclinical development is planned for early 2014. The first in human clinical trial is expected to start in 2015.